
## Anne-Marie Heegaard

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8499696/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Targeted disruption of the biglycan gene leads to an osteoporosis-like phenotype in mice. Nature Genetics, 1998, 20, 78-82.	21.4	543
2	Proteinases in bone resorption: obvious and less obvious roles. Clinica Chimica Acta, 2000, 291, 223-234.	1.1	181
3	Best practice management guidelines for fibrous dysplasia/McCune-Albright syndrome: a consensus statement from the FD/MAS international consortium. Orphanet Journal of Rare Diseases, 2019, 14, 139.	2.7	149
4	A Reverse J-Shaped Association Between Serum 25-Hydroxyvitamin D and Cardiovascular Disease Mortality: The CopD Study. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2339-2346.	3.6	143
5	Pain without Nociceptors? Nav1.7-Independent Pain Mechanisms. Cell Reports, 2014, 6, 301-312.	6.4	141
6	Acidification of the Osteoclastic Resorption Compartment Provides Insight into the Coupling of Bone Formation to Bone Resorption. American Journal of Pathology, 2005, 166, 467-476.	3.8	140
7	The Chloride Channel Inhibitor NS3736 Prevents Bone Resorption in Ovariectomized Rats Without Changing Bone Formation. Journal of Bone and Mineral Research, 2004, 19, 1144-1153.	2.8	136
8	Differential activation of spinal cord glial cells in murine models of neuropathic and cancer pain. European Journal of Pain, 2009, 13, 138-145.	2.8	127
9	Biglycan Deficiency Causes Spontaneous Aortic Dissection and Rupture in Mice. Circulation, 2007, 115, 2731-2738.	1.6	126
10	Biglycan deficiency increases osteoclast differentiation and activity due to defective osteoblasts. Bone, 2006, 38, 778-786.	2.9	80
11	P2X7 receptor-deficient mice are susceptible to bone cancer pain. Pain, 2011, 152, 1766-1776.	4.2	63
12	Chronic administration of the selective P2X3, P2X2/3 receptor antagonist, A-317491, transiently attenuates cancer-induced bone pain in mice. European Journal of Pharmacology, 2012, 688, 27-34.	3.5	61
13	Neuropeptide Y and its Involvement in Chronic Pain. Neuroscience, 2018, 387, 162-169.	2.3	57
14	Synthetic matrix metalloproteinase inhibitors inhibit growth of established breast cancer osteolytic lesions and prolong survival in mice. Clinical Cancer Research, 2002, 8, 1932-9.	7.0	55
15	Innervation is higher above Bone Remodeling Surfaces and in Cortical Pores in Human Bone: Lessons from patients with primary hyperparathyroidism. Scientific Reports, 2019, 9, 5361.	3.3	48
16	Doxycycline-coated sutures improve mechanical strength of intestinal anastomoses. International Journal of Colorectal Disease, 2008, 23, 271-276.	2.2	47
17	Biglycan Deficiency Interferes With Ovariectomy-Induced Bone Loss. Journal of Bone and Mineral Research, 2003, 18, 2152-2158.	2.8	46
18	P2X7 receptor-mediated analgesia in cancer-induced bone pain. Neuroscience, 2015, 291, 93-105.	2.3	36

#	Article	IF	CITATIONS
19	Differential effects of repeated low dose treatment with the cannabinoid agonist WIN 55,212-2 in experimental models of bone cancer pain and neuropathic pain. Pharmacology Biochemistry and Behavior, 2008, 91, 38-46.	2.9	35
20	The Src family kinase inhibitor dasatinib delays pain-related behaviour and conserves bone in a rat model of cancer-induced bone pain. Scientific Reports, 2017, 7, 4792.	3.3	32
21	Functional Characterization of the Human Biglycan 5′-Flanking DNA and Binding of the Transcription Factor c-Krox. Journal of Bone and Mineral Research, 1997, 12, 2050-2060.	2.8	28
22	MOLECULAR AND CELLULAR BIOLOGY OF THE MAJOR NONCOLLAGENOUS PROTEINS IN BONE. , 1993, , 191-23	4.	27
23	Transforming growth factor beta stimulation of biglycan gene expression is potentially mediated by sp1 binding factors. Journal of Cellular Biochemistry, 2004, 93, 463-475.	2.6	25
24	Vitamin D levels and cancer incidence in 217,244 individuals from primary health care in Denmark. International Journal of Cancer, 2019, 145, 338-346.	5.1	25
25	Nonselective matrix metalloproteinase but not tumor necrosis factor-α inhibition effectively preserves the early critical colon anastomotic integrity. International Journal of Colorectal Disease, 2011, 26, 329-337.	2.2	23
26	The Role of Purinergic Receptors in Cancer-Induced Bone Pain. Journal of Osteoporosis, 2012, 2012, 1-12.	0.5	22
27	Co-administration of morphine and gabapentin leads to dose dependent synergistic effects in a rat model of postoperative pain. European Journal of Pharmaceutical Sciences, 2016, 82, 97-105.	4.0	22
28	Influence of sex differences on the progression of cancer-induced bone pain. Anticancer Research, 2013, 33, 1963-9.	1.1	22
29	Vitamin D levels and the risk of prostate cancer and prostate cancer mortality. Acta Oncológica, 2021, 60, 316-322.	1.8	20
30	Cancerâ€induced bone loss and associated painâ€related behavior is reduced by risedronate but not its phosphonocarboxylate analog NEâ€10790. International Journal of Cancer, 2009, 125, 1177-1185.	5.1	19
31	Bone pain: current and future treatments. Current Opinion in Pharmacology, 2016, 28, 31-37.	3.5	19
32	The effect of gender on early colonic anastomotic wound healing. International Journal of Colorectal Disease, 2018, 33, 1269-1276.	2.2	16
33	R andall S elitto pressure algometry for assessment of boneâ€related pain in rats. European Journal of Pain, 2015, 19, 305-312.	2.8	15
34	Neuropeptide Y is Up-regulated and Induces Antinociception in Cancer-induced Bone Pain. Neuroscience, 2018, 384, 111-119.	2.3	15
35	Chronic high dose P2X7 receptor inhibition exacerbates cancer-induced bone pain. European Journal of Pharmacology, 2019, 845, 48-55.	3.5	15
36	Cancer-induced Bone Pain Impairs Burrowing Behaviour in Mouse and Rat. In Vivo, 2019, 33, 1125-1132.	1.3	13

Anne-Marie Heegaard

#	Article	IF	CITATIONS
37	Decitabine attenuates nociceptive behavior in a murine model of bone cancer pain. Pain, 2019, 160, 619-631.	4.2	11
38	Modulation of Rat Cancer-Induced Bone Pain is Independent of Spinal Microglia Activity. Cancers, 2020, 12, 2740.	3.7	10
39	Multiple myeloma—A painful disease of the bone marrow. Seminars in Cell and Developmental Biology, 2021, 112, 49-58.	5.0	10
40	Differential Painâ€Related Behaviors and Bone Disease in Immunocompetent Mouse Models of Myeloma. JBMR Plus, 2020, 4, e10252.	2.7	9
41	Effect of sex in the MRMT-1 model of cancer-induced bone pain. F1000Research, 2015, 4, 445.	1.6	9
42	Neuropathic-like Pain in Fibrous Dysplasia/McCune-Albright Syndrome. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2258-e2266.	3.6	9
43	The nociceptin/orphanin FQ receptor system as a target to alleviate cancerâ€induced bone pain in rats: Model validation and pharmacological evaluation. British Journal of Pharmacology, 2021, 178, 1995-2007.	5.4	8
44	Sex-difference affects disease progression in the MRMT-1 model of cancer-induced bone pain. F1000Research, 2015, 4, 445.	1.6	7
45	Fibrous dysplasia animal models: A systematic review. Bone, 2022, 155, 116270.	2.9	6
46	Systematic review and meta-analysis of studies in which burrowing behaviour was assessed in rodent models of disease-associated persistent pain. Pain, 2022, 163, 2076-2102.	4.2	6
47	Quantification of the Pharmacodynamic Interaction of Morphine and Gabapentin Using a Response Surface Approach. AAPS Journal, 2017, 19, 1804-1813.	4.4	5
48	Bone Pain in Multiple Myeloma (BPMM)—A Protocol for a Prospective, Longitudinal, Observational Study. Cancers, 2021, 13, 1596.	3.7	5
49	Exploring the Patients' Perception of Background and Breakthrough Pain: A McGill Pain Questionnaire Inquiry in Patients with Bone Cancer Pain. Journal of Palliative Medicine, 2019, 22, 881-883.	1.1	4
50	Hypophosphatemic Hypovitaminosis D Induces Osteomalacia in the Adult Female Rat. Endocrinology, 2020, 161, .	2.8	4
51	Neuronal Sprouting and Reorganization in Bone Tissue Infiltrated by Human Breast Cancer Cells. Frontiers in Pain Research, 0, 3, .	2.0	ο